MPM BioImpact Holds 8.6% Of Corbus — The Adviser Says It Isn't Seeking Control

Corbus is advancing a late-stage cancer trial alongside an early-stage obesity drug study.

Share
MPM BioImpact Holds 8.6% Of Corbus — The Adviser Says It Isn't Seeking Control

MPM BioImpact, an investment adviser, reported an 8.6% stake in Corbus Pharmaceuticals, which develops experimental cancer and obesity treatments, in an SEC ownership disclosure filed Friday. The adviser certified that the holding was not intended to change or influence control of the company.

1.7 Million Shares, Sole Voting Power

MPM BioImpact's position comprised 1,667,272 shares as of September 30, 2026. The adviser reported sole authority to vote and dispose of those shares.

The passive ownership disclosure places the investment within MPM BioImpact's ordinary business activities. Its certification covers both the purchase and continued holding of the securities.

Cancer Trial Targets An Approval Path

Corbus began dosing patients in September in TEMPO-1, its late-stage oropharyngeal cancer study, according to the company's corporate update. The FDA cleared the study in July 2026.

The trial compares sutantatug envedotin with treatments selected by investigators for patients whose cancer has previously been treated. Corbus intends to use tumor-response findings to support potential accelerated approval, with overall-survival findings supporting conversion to full approval.

Corbus has no approved products for sale. Its cancer candidate CRB-701 delivers a cell-killing payload by targeting the Nectin-4 protein on cancer cells. Corbus licenses it from CSPC for the United States, Canada, European Union, United Kingdom and Australia.

The company relies on contract manufacturers and licensing partners for drug supply and owns no manufacturing facilities. Research and development spending totaled $70.1 million in 2025.

Obesity Pill Posts Early Weight Loss

Participants taking 60 mg daily of CRB-913 recorded mean weight loss of 5% after 12 weeks in an early-stage study, Corbus reported. The company said weight loss had not reached a plateau.

CRB-913 is an oral obesity treatment that blocks the cannabinoid type-1 receptor. Its early-stage study includes 240 U.S. participants.

Corbus had a market capitalization of $70 million in Friday trading as of 12:34 p.m. ET.

Corbus expects first-quarter 2027 results from testing sutantatug envedotin with Keytruda as an initial treatment for oropharyngeal cancer.

Sources

More on Corbus Pharmaceuticals

All Corbus Pharmaceuticals (CRBP) coverage →